Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1097/MD.0000000000030680 http://hdl.handle.net/11449/247628 |
Resumo: | Introduction: Most contraceptive combinations can interfere with the processes of bone formation and resorption. Aim: The aim of this study was to evaluate the effect of 2 combinations of low-dose oral hormonal contraceptives (20 µg ethinyl estradiol [EE]/150 mg desogestrel [COC1] or 30 µg EE/3 mg drospirenone [COC2]) on bone mass acquisition in adolescents over 2 years by means of bone densitometry and measurement of biomarkers of bone remodeling. Methods: Parallel-group, non-randomized controlled clinical trial of 127 adolescents divided into a control group and 2 groups receiving either COC1 or COC2. The participants were submitted to anthropometric assessment and evaluation of secondary sexual characteristics (Tanner criteria) and bone age. Bone densitometry by dual-energy X-ray absorptiometry and measurement of bone biomarkers (bone alkaline phosphatase, osteocalcin, and C-terminal telopeptide) were performed at baseline and after 24 months. Results: No significant differences in the variables analyzed were observed between COC1 or COC2 users and the control group at baseline. After 24 months, non-users had incorporated more bone mass (content and density) than either group of contraceptive users. This negative impact was more pronounced in the COC2 group than in the COC1 group. A significant reduction in the percentage values of bone alkaline phosphatase and osteocalcin was observed in users of oral contraceptives. Conclusion: Bone mass acquisition was compromised in adolescent users of combined hormonal contraceptives. The negative impact was more pronounced in adolescents using contraceptives that contain 30 µg EE/3 mg drospirenone. |
id |
UNSP_4b33fd8a10b2e1ee810c92199bd43890 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/247628 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-upadolescentsbone densitybone remodelingbone resorptionhormonal contraceptivespeak height velocity (PHV)Introduction: Most contraceptive combinations can interfere with the processes of bone formation and resorption. Aim: The aim of this study was to evaluate the effect of 2 combinations of low-dose oral hormonal contraceptives (20 µg ethinyl estradiol [EE]/150 mg desogestrel [COC1] or 30 µg EE/3 mg drospirenone [COC2]) on bone mass acquisition in adolescents over 2 years by means of bone densitometry and measurement of biomarkers of bone remodeling. Methods: Parallel-group, non-randomized controlled clinical trial of 127 adolescents divided into a control group and 2 groups receiving either COC1 or COC2. The participants were submitted to anthropometric assessment and evaluation of secondary sexual characteristics (Tanner criteria) and bone age. Bone densitometry by dual-energy X-ray absorptiometry and measurement of bone biomarkers (bone alkaline phosphatase, osteocalcin, and C-terminal telopeptide) were performed at baseline and after 24 months. Results: No significant differences in the variables analyzed were observed between COC1 or COC2 users and the control group at baseline. After 24 months, non-users had incorporated more bone mass (content and density) than either group of contraceptive users. This negative impact was more pronounced in the COC2 group than in the COC1 group. A significant reduction in the percentage values of bone alkaline phosphatase and osteocalcin was observed in users of oral contraceptives. Conclusion: Bone mass acquisition was compromised in adolescent users of combined hormonal contraceptives. The negative impact was more pronounced in adolescents using contraceptives that contain 30 µg EE/3 mg drospirenone.Postgraduate Program in Tocogynecology Botucatu Medical School São Paulo State University (UNESP), São PauloMedical School Assis Municipality Educational Foundation (FEMA), SPState University of Londrina UEL, ParanaDepartment of Tropical Diseases and Diagnostic Imaging Botucatu Medical School São Paulo University (UNESP), São PauloBotucatu Medical School São Paulo State University (UNESP), São PauloPostgraduate Program in Tocogynecology Botucatu Medical School São Paulo State University (UNESP), São PauloDepartment of Tropical Diseases and Diagnostic Imaging Botucatu Medical School São Paulo University (UNESP), São PauloBotucatu Medical School São Paulo State University (UNESP), São PauloUniversidade Estadual Paulista (UNESP)Assis Municipality Educational Foundation (FEMA)Universidade Estadual de Londrina (UEL)Caldeirão, Talita Domingues [UNESP]Orsolini, Lilian Rodrigues [UNESP]Da Silva, Carla CristianeBisi Rizzo, Anapaula Da Conceição [UNESP]Teixeira, Altamir Santos [UNESP]Nunes, Hélio Rubens De Carvalho [UNESP]Goldberg, Tamara Beres Lederer [UNESP]2023-07-29T13:21:22Z2023-07-29T13:21:22Z2022-09-16info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleE30680http://dx.doi.org/10.1097/MD.0000000000030680Medicine (United States), v. 101, n. 37, p. E30680-, 2022.1536-59640025-7974http://hdl.handle.net/11449/24762810.1097/MD.00000000000306802-s2.0-85138193063Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengMedicine (United States)info:eu-repo/semantics/openAccess2023-07-29T13:21:22Zoai:repositorio.unesp.br:11449/247628Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462023-07-29T13:21:22Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
title |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
spellingShingle |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up Caldeirão, Talita Domingues [UNESP] adolescents bone density bone remodeling bone resorption hormonal contraceptives peak height velocity (PHV) |
title_short |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
title_full |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
title_fullStr |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
title_full_unstemmed |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
title_sort |
Effect of two combinations of low-dose oral contraceptives on adolescent bone mass: A clinical trial with 2 years follow-up |
author |
Caldeirão, Talita Domingues [UNESP] |
author_facet |
Caldeirão, Talita Domingues [UNESP] Orsolini, Lilian Rodrigues [UNESP] Da Silva, Carla Cristiane Bisi Rizzo, Anapaula Da Conceição [UNESP] Teixeira, Altamir Santos [UNESP] Nunes, Hélio Rubens De Carvalho [UNESP] Goldberg, Tamara Beres Lederer [UNESP] |
author_role |
author |
author2 |
Orsolini, Lilian Rodrigues [UNESP] Da Silva, Carla Cristiane Bisi Rizzo, Anapaula Da Conceição [UNESP] Teixeira, Altamir Santos [UNESP] Nunes, Hélio Rubens De Carvalho [UNESP] Goldberg, Tamara Beres Lederer [UNESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (UNESP) Assis Municipality Educational Foundation (FEMA) Universidade Estadual de Londrina (UEL) |
dc.contributor.author.fl_str_mv |
Caldeirão, Talita Domingues [UNESP] Orsolini, Lilian Rodrigues [UNESP] Da Silva, Carla Cristiane Bisi Rizzo, Anapaula Da Conceição [UNESP] Teixeira, Altamir Santos [UNESP] Nunes, Hélio Rubens De Carvalho [UNESP] Goldberg, Tamara Beres Lederer [UNESP] |
dc.subject.por.fl_str_mv |
adolescents bone density bone remodeling bone resorption hormonal contraceptives peak height velocity (PHV) |
topic |
adolescents bone density bone remodeling bone resorption hormonal contraceptives peak height velocity (PHV) |
description |
Introduction: Most contraceptive combinations can interfere with the processes of bone formation and resorption. Aim: The aim of this study was to evaluate the effect of 2 combinations of low-dose oral hormonal contraceptives (20 µg ethinyl estradiol [EE]/150 mg desogestrel [COC1] or 30 µg EE/3 mg drospirenone [COC2]) on bone mass acquisition in adolescents over 2 years by means of bone densitometry and measurement of biomarkers of bone remodeling. Methods: Parallel-group, non-randomized controlled clinical trial of 127 adolescents divided into a control group and 2 groups receiving either COC1 or COC2. The participants were submitted to anthropometric assessment and evaluation of secondary sexual characteristics (Tanner criteria) and bone age. Bone densitometry by dual-energy X-ray absorptiometry and measurement of bone biomarkers (bone alkaline phosphatase, osteocalcin, and C-terminal telopeptide) were performed at baseline and after 24 months. Results: No significant differences in the variables analyzed were observed between COC1 or COC2 users and the control group at baseline. After 24 months, non-users had incorporated more bone mass (content and density) than either group of contraceptive users. This negative impact was more pronounced in the COC2 group than in the COC1 group. A significant reduction in the percentage values of bone alkaline phosphatase and osteocalcin was observed in users of oral contraceptives. Conclusion: Bone mass acquisition was compromised in adolescent users of combined hormonal contraceptives. The negative impact was more pronounced in adolescents using contraceptives that contain 30 µg EE/3 mg drospirenone. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-16 2023-07-29T13:21:22Z 2023-07-29T13:21:22Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1097/MD.0000000000030680 Medicine (United States), v. 101, n. 37, p. E30680-, 2022. 1536-5964 0025-7974 http://hdl.handle.net/11449/247628 10.1097/MD.0000000000030680 2-s2.0-85138193063 |
url |
http://dx.doi.org/10.1097/MD.0000000000030680 http://hdl.handle.net/11449/247628 |
identifier_str_mv |
Medicine (United States), v. 101, n. 37, p. E30680-, 2022. 1536-5964 0025-7974 10.1097/MD.0000000000030680 2-s2.0-85138193063 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Medicine (United States) |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
E30680 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1803046154528620544 |